Antibody Drug Conjugates have become one of the emerging divisions in oncology pipelines. Recent industry tracking suggests that over 200 ADC candidates are actively being developed in the world today, with complexity escalating at every stage. Science is no longer the bottleneck, but manufacturing is.
This blog breaks down how advanced bioconjugation techniques are shaping modern adc cdmo production, why sponsor companies rely heavily on specialized partners and what practical lessons emerge when scaling these systems for clinical and commercial supply.
ADC performance depends on three elements working together: the antibody, the linker and the payload. It is in bioconjugation that these parts are incorporated as an entity of functionality. Even a minor variation in this procedure may change its efficacy, toxicity, or stability.
Early ADC programs relied on random conjugation methods. That approach worked, but produced heterogeneous products. The standards of regulation have since changed. The tight control of the drug-to-antibody ratio, consistency, and reproducibility is now required.
This shift explains why sponsors increasingly engage an api cdmo or ADC focused partner early in development, rather than retrofitting processes later.
Traditional lysine-based conjugation attaches payloads at multiple sites on the antibody. This creates variability and complicates characterization.
Modern approaches favor site-specific methods, which deliver:
• Defined conjugation sites
• Narrow drug-to-antibody ratio distributions
• Improved batch-to-batch consistency
Controlled conjugation is no longer optional for late-stage ADC programs.
Enzymatic techniques use engineered enzymes to attach payloads at precise locations. Transglutaminase and glycosylation-based strategies are common examples.
Key advantages include:
• High selectivity
• Mild reaction conditions
• Reduced antibody degradation
Many adc cdmo facilities now maintain dedicated enzyme platforms validated for GMP use.
Cysteine rebridging allows payload attachment without disrupting antibody structure. The original disulfide bonds are preserved, maintaining stability while enabling precise conjugation.
This approach offers:
• Improved plasma stability
• Lower aggregation risk
• Better pharmacokinetic profiles
This route is often favored by sponsors driving towards greater potency payloads because of safety issues.
Payloads are composed of very potent compounds, and the occupational exposure limits of the compounds are in the nanograms. Special confinement systems are needed.
Experienced abs cdmo and adc partners invest heavily in:
• Isolator-based systems
• Closed transfer technologies
• Dedicated waste handling procedures
This infrastructure is difficult to retrofit, which is why early CDMO selection matters.
Bioconjugation that works at the gram scale may fail at the kilogram scale. Mixing efficiency, reaction kinetics, and quenching behavior all change.
Lessons learned from commercial ADC programs show that:
• Scale-down models are critical
• Analytical methods must evolve with scale
• Tech transfer timelines are often underestimated
ADC CDMO teams with commercial experience tend to identify these risks early.
Advanced bioconjugation requires equally advanced analytics. DAR determination, free drug quantification, and aggregate profiling are non-negotiable.
Leading api cdmo partners integrate analytics directly into process development, not as a downstream check.
A mid-stage oncology company recently transitioned an ADC from Phase II to commercial readiness. Early batches showed variability in DAR distribution.
The solution was not a new linker or payload. The fix came from process refinement:
• Switching to a site-specific conjugation strategy
• Introducing tighter in-process controls
• Aligning analytical release criteria with regulatory expectations
This transition shortened regulatory review and reduced batch rejection risk. The takeaway is simple. Manufacturing design decisions shape regulatory outcomes.
Selecting the right partner goes beyond capacity.
Key indicators of maturity include:
• Proven site-specific conjugation platforms
• Integrated HPAPI handling and biologics expertise
• Experience with late-stage and commercial ADCs
• Transparent process development data
Sponsors benefit most when CDMO teams act as technical collaborators, not just manufacturers.
Advanced bioconjugation is now central to ADC success. Precision, control, and scalability define programs that move smoothly from clinic to market. The ability to invest early in the appropriate technical strategies by sponsors helps them to avoid expensive redesigns in the future.
The ADC landscape will continue to evolve, but one trend is clear. The manufacturing excellence has become a competitive advantage. Platforms that match innovators with specialized partners are useful in facilitating that advancement throughout the ADC ecosystem, including the MAI CDMO Network.
If you have any questions or suggestions, click here. We will be happy to assist you.
